Mohamed Sikkander Abdul Razak: Addressing Underdiagnosis of Bleeding Disorders in Women With Heavy Menstrual Bleeding
Mohamed Sikkander Abdul Razak, Professor at GKM College of Engineering Technology, shared Heghine Khachatryan’s post on LinkedIn:
“1. Heavy menstrual bleeding (HMB) is described as:
The most common bleeding manifestation of underlying hemostatic defects, often underdiagnosed.
2. The mechanistic pathway explaining why bleeding occurs involves:
- Endothelial integrity and angiogenesis: estrogen and progesterone cause a fragile endometrium with increased vascular density.
- Primary hemostasis defect: von Willebrand factor (vWF) or platelet dysfunction – impaired adhesion and aggregation.
- Secondary hemostasis impairment: reduced thrombin generation or fibrinolysis – unstable fibrin clot.
- Clinical outcome: excessive and prolonged menstrual bleeding (HMB).
3. Most common causes of HMB are:
- von Willebrand disease (vWD).
- Platelet function disorders.
- Mild factor deficiencies.
4. During pregnancy, hemostatic changes:
- Mask bleeding disorders, but risks resurface as:
- Increased miscarriage (early placental hemostasis failure).
- Postpartum hemorrhage (rapid fibrinolysis plus uterine atony).
- Maternal morbidity (unrecognized vWD or platelet defects).
5. Misdiagnosis of HMB can lead to:
- Delayed diagnosis.
- Severe anemia.
- Obstetric and surgical complications.
- Preventable morbidity.
6. HMB is often the:
First and only warning sign of a bleeding disorder.
7. Call to action for HMB management:
Hematologic evaluation is indicated in ALL women with HMB, especially:
- Adolescents.
- Those with iron deficiency or bleeding history.
- Those planning pregnancy or surgery.
8. Key message about HMB:
It is not a ‘gynecologic’ issue; it is a hemostatic disorder until proven otherwise.”
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:
“Heavy menstrual bleeding is not ‘normal’ — it is often missed pathology.
For too long, heavy menstrual bleeding (HMB) has been normalized, underestimated, and frequently misdiagnosed.
Behind what is often dismissed as a ‘gynecological issue’, there may be an underlying hemostatic disorder — including von Willebrand disease, platelet function defects, or other coagulation abnormalities.
The clinical reality is concerning:
Many women remain undiagnosed for years, presenting later with anemia, perioperative bleeding, or complications during pregnancy and childbirth.
Pregnancy introduces an additional layer of complexity.
Hemostasis is dynamically altered, and in women with unrecognized bleeding disorders, this may result in:
- increased risk of miscarriage
- postpartum hemorrhage
- preventable maternal morbidity
Misdiagnosis is not benign — it is systemic failure.
We must shift from symptom-based reassurance to structured hemostatic evaluation, especially in:
- adolescents with HMB
- women with iron deficiency
- patients with bleeding history prior to surgical or reproductive interventions
This is not only a clinical issue — it is a matter of health equity, awareness, and diagnostic capacity.
The time has come to integrate hemostasis into routine women’s health assessment — not as an exception, but as a standard.”

Other posts featuring Mohamed Sikkander Abdul Razak on Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series